DNMT۳A gene mutations in acute myeloid leukemia and acute lymphoid leukemia

سال انتشار: 1398
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 166

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

AGOC05_034

تاریخ نمایه سازی: 25 مرداد 1401

چکیده مقاله:

Introduction and Aims: DNA methyltransferase۳A (DNMT۳A) is necessary for the adjustment of gene expression and the mutations in the DNMT۳A gene are reported in a variety of leukemia cases. DNMT۳A mutations are during cancer progression and cause poor prognosis in many leukemias. Thus, this gene can be as a target for new treatments. This study aimed to examine the distribution of DNMT۳A mutations in Iranian Acute leukemia patients .Materials and Methods: In this study, diagnostic samples from ۴۵ patients with de novo Acute Leukemia, including ۲۳ AML patients and ۲۲ ALL patients were screened, from May ۲۰۱۷ to February ۲۰۱۸ for incidence DNMT۳A mutations by PCR and direct sequencing .Results: A total of ۲ (۹.۱%) AML cases and ۱(۴.۳۴%) ALL case were found to have the DNMT۳A R۸۸۲H mutation .we found a total of ۲۲.۷% and ۲۱.۷% of patients with AML and ALL had polymorphism rs۳۶۸۵۱۶۵۴۳ respectively. No significant correlation was found between platelet count, Hemoglobin levels, WBC count, blast percent of bone marrow, FLT۳ mutations, CEBPA mutations, NPM۱ mutations, FAB classification, and cytogenetic abnormalities with DNMT۳A mutations. DNMT۳A mutations were considerably associated with higher age in AML patients .Conclusions: The findings suggest that the DNMT۳A mutations are probably new biomarker in the early examination and treatment of acute leukemia, although further studies are needed to assess prognosis and comparison between AML and ALL patients.

نویسندگان

Parisa Bagheri

Department of Hematology and Blood Banking , Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.MSc in Hematology and Blood Banking, Dep. of Medical Hematology and Blood Banking , Paramedical School, Gerash Universityof Medical Sci

Hossein Ayatollahi

Cancer Molecular Pathology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

farhad zaker

Department of Hematology and Blood Banking, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran,Iran

Mohammad Hadi Sadeghian

Cancer Molecular Pathology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

soodeh namjoo

Department of Hematology and Blood Banking, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran,Iran